Our Pricing

Wegovy Side Effects UK: What Clinical Trials Show

Understanding wegovy side effects uk clinical trials data helps you make informed treatment decisions. At Cured Pharmacy, our UK clinical team has supported thousands of patients starting semaglutide therapy, and we've compiled evidence-based guidance from the landmark STEP trials to help you know exactly what to expect.

What the STEP Clinical Trials Revealed About Wegovy Side Effects UK

The STEP (Semaglutide Treatment Effect in People with obesity) trial programme enrolled over 4,500 participants across multiple countries, providing the most comprehensive safety data available for semaglutide 2.4mg [1]. These phase 3 trials tracked adverse events systematically over 68 weeks, revealing that 74% of participants experienced at least one treatment-emergent adverse event, though most were mild to moderate in severity.

Gastrointestinal side effects dominated the safety profile in STEP trials. Nausea occurred in 44% of participants on Wegovy versus 17% on placebo, whilst vomiting affected 24% compared to 6% on placebo [1]. Importantly, these symptoms typically emerged during dose escalation and diminished over time — 95% of gastrointestinal events were classified as mild or moderate, with only 4.5% of participants discontinuing treatment due to GI intolerance [2].

Superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that whilst clinical trial data provides essential context, individual tolerance varies considerably. At Cured Pharmacy, our UK prescribers assess your medical history during the free online consultation to determine whether Wegovy's benefit-risk profile aligns with your circumstances.

Common Wegovy Side Effects: Frequency and Duration

Gastrointestinal symptoms represent the most frequently reported adverse events with semaglutide therapy. In the STEP-1 trial, nausea peaked during the initial 0.25mg and 0.5mg dose escalation phases, typically resolving within 4-8 weeks as the body adapted to GLP-1 receptor activation [1]. Diarrhoea occurred in 30% of participants, constipation in 24%, and abdominal pain in 20%, with symptom severity generally decreasing after reaching maintenance doses.

Headache affected approximately 14% of trial participants, whilst fatigue was reported in 11% [2]. These non-gastrointestinal effects showed less clear correlation with dose escalation timing and varied more widely between individuals. Injection site reactions — including redness, swelling or discomfort at the subcutaneous injection site — occurred in roughly 8% of participants but rarely led to treatment discontinuation.

Clinical experience at Cured Pharmacy mirrors these trial findings. Most patients starting at £79.00 report that initial nausea subsides within the first month, particularly when following structured dietary guidance during dose titration. Our UK clinical team provides specific management strategies during your consultation to minimise symptom burden.

Timeline of Side Effect Resolution

STEP trial data demonstrates that 80% of participants who experienced nausea reported symptom improvement or complete resolution by week 20 of treatment [1]. This pattern reflects physiological adaptation to GLP-1 receptor agonism, as the body adjusts to altered gastric emptying rates and satiety signalling. Patients who maintain slower dose escalation schedules — extending time at lower doses before increasing — typically report fewer severe gastrointestinal symptoms.

Managing Wegovy Nausea: Evidence-Based Strategies

The STEP trials identified several factors that influenced nausea severity, providing practical guidance for symptom management. Participants who consumed smaller, more frequent meals reported lower nausea scores than those maintaining three large daily meals [2]. Avoiding high-fat foods during the first 12 weeks of treatment also correlated with reduced gastrointestinal distress, as fatty meals delay gastric emptying further when combined with semaglutide's effects.

Timing your Wegovy injection relative to meals does not significantly impact absorption — the medication can be administered at any time of day, with or without food [1]. However, many patients find that injecting in the evening reduces daytime nausea perception. Staying well-hydrated throughout treatment supports gastric function and may alleviate constipation, which affected nearly one-quarter of STEP participants.

At Cured Pharmacy, our UK prescribers can adjust your dose escalation schedule if initial side effects prove troublesome. Extending time at the 0.25mg or 0.5mg starter doses beyond the standard 4-week intervals allows for gentler physiological adaptation whilst maintaining treatment efficacy. All prescription adjustments require clinical assessment to ensure safety and appropriateness for your individual circumstances.

When to Contact Your Prescriber

Whilst most Wegovy side effects resolve without intervention, certain symptoms warrant immediate clinical review. Severe abdominal pain, persistent vomiting lasting more than 24 hours, or signs of pancreatitis (severe upper abdominal pain radiating to the back) require urgent medical assessment [2]. The STEP trials recorded pancreatitis in 0.2% of semaglutide participants, emphasising the importance of recognising warning signs early. Contact Cured Pharmacy on (+44) 116 4646009 if you experience concerning symptoms whilst on treatment.

Serious Adverse Events in Wegovy Clinical Trials

Serious adverse events (SAEs) occurred in 9.8% of Wegovy participants versus 6.4% in placebo groups across the STEP programme, though most were judged unrelated to study medication [1]. Cholelithiasis (gallstones) emerged as the most common treatment-related SAE, affecting 1.6% of semaglutide participants compared to 0.7% on placebo. This elevated risk likely reflects rapid weight loss rather than direct medication toxicity, as gallstone formation increases with any substantial caloric deficit.

Cardiovascular safety data from STEP trials proved reassuring. Heart rate increases of 1-4 beats per minute occurred with semaglutide treatment, but no significant differences in major adverse cardiovascular events emerged between treatment and placebo groups [2]. The ongoing SELECT cardiovascular outcomes trial will provide longer-term safety data for semaglutide in patients with established cardiovascular disease.

Thyroid C-cell tumours appeared in rodent studies at exposures similar to human therapeutic doses, leading to a boxed warning in US prescribing information [1]. However, no cases of medullary thyroid carcinoma occurred in the STEP trials, and the relevance of rodent findings to human risk remains uncertain. Wegovy remains contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.

Wegovy Side Effects vs Other Weight Loss Treatments

Comparing safety profiles across weight loss medications helps contextualise Wegovy's tolerability. Orlistat, the most established NHS-recommended option, causes gastrointestinal effects in up to 80% of users — primarily fatty stools, faecal urgency and anal leakage due to fat malabsorption [3]. Whilst these differ mechanistically from Wegovy's nausea-predominant profile, both medications require tolerance of digestive symptoms for successful treatment.

Liraglutide 3.0mg (Saxenda), the earlier-generation GLP-1 receptor agonist, demonstrated similar gastrointestinal side effect rates to semaglutide in head-to-head comparisons, with nausea affecting 39% of participants [4]. However, Saxenda requires daily rather than weekly injection, potentially increasing injection site reaction frequency. Tirzepatide (Mounjaro), the dual GIP/GLP-1 receptor agonist, showed comparable nausea rates of 33-36% in SURMOUNT trials, suggesting GI effects represent a class characteristic of incretin-based therapies.

At Cured Pharmacy, treatment selection depends on your individual medical history, weight loss goals, and tolerance for specific side effect profiles. Our UK clinical team assesses these factors during your free online consultation, which takes under 3 minutes to complete. All medications require prescription approval from a UK-registered prescriber based on clinical appropriateness.

Safety Monitoring During Treatment

STEP trial protocols included regular monitoring of lipase levels, renal function, and heart rate throughout the 68-week treatment period [1]. Whilst such intensive monitoring isn't standard in routine clinical practice, patients with pre-existing conditions may benefit from periodic blood tests. Your UK prescriber will recommend appropriate follow-up based on your medical history and risk factors identified during assessment.

Long-Term Safety Data and Ongoing Research

The STEP trials followed participants for 68 weeks, providing robust medium-term safety data for Wegovy [1]. Extension studies tracking patients beyond two years have not identified new safety signals, though gastrointestinal tolerance typically improves substantially after the first 6 months of treatment. Real-world safety monitoring through the MHRA's Yellow Card scheme continues to track adverse events in UK patients, with the safety profile remaining consistent with clinical trial findings.

Emerging research addresses specific safety questions raised by earlier trials. The FLOW trial, evaluating semaglutide in patients with type 2 diabetes and chronic kidney disease, will provide crucial data on renal safety in vulnerable populations [2]. Similarly, the SELECT cardiovascular outcomes trial examines whether semaglutide's weight loss benefits translate to reduced cardiovascular events in patients with established heart disease, with results expected to inform prescribing guidance.

At Cured Pharmacy, we maintain current knowledge of evolving safety data to ensure our clinical team provides evidence-based guidance. Superintendent pharmacist Tarun Kumar regularly reviews updates from the MHRA and NICE to inform our prescribing protocols. When you start Wegovy at our UK-registered pharmacy (GPhC 9012511), you receive ongoing support from prescribers who understand both the clinical trial evidence and real-world patient experiences with semaglutide therapy.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Sjöström, L., Rissanen, A., Andersen, T., et al. (1998). Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. The Lancet, 352(9123), 167–172. https://doi.org/10.1016/S0140-6736(97)11509-4
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. The side effect data presented reflects clinical trial findings and may not represent individual experiences. Contact your prescriber immediately if you experience severe or concerning symptoms whilst taking Wegovy.